108 results match your criteria: "Neuroimmunology Clinic[Affiliation]"

High-Field-Blinded Assessment of Portable Ultra-Low-Field Brain MRI for Multiple Sclerosis.

J Neuroimaging

January 2025

Translational Neuroradiology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.

Background And Purpose: MRI is crucial for multiple sclerosis (MS), but the relative value of portable ultra-low field MRI (pULF-MRI), a technology that holds promise for extending access to MRI, is unknown. We assessed white matter lesion (WML) detection on pULF-MRI compared to high-field MRI (HF-MRI), focusing on blinded assessments, assessor self-training, and multiplanar acquisitions.

Methods: Fifty-five adults with MS underwent pULF-MRI following their HF-MRI.

View Article and Find Full Text PDF

Background: We evaluated comprehension and application of the 2015 neuromyelitis optica spectrum disorder (NMOSD) criteria core elements by neurologists in Latin America (LATAM) who routinely diagnose and care for NMOSD patients by (i) identifying typical/suggestive NMOSD syndromes, (ii) detecting typical MRI NMOSD lesions and meeting MRI dissemination in space (DIS) criteria, and (iii) evaluating historical symptoms suggestive of NMOSD.

Methods: We conducted an anonymous, voluntary, self-administered web- and case-based survey cross-sectional study from October 2023 to January 2024 of neurologists identified through the LACTRIMS database. Questions were presented first through iterative clinical cases or imaging, followed by questions directly evaluating comprehension of definitions.

View Article and Find Full Text PDF

Exploring the role of sex hormones and gender diversity in multiple sclerosis.

Nat Rev Neurol

January 2025

Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia.

Sex and sex hormones are thought to influence multiple sclerosis (MS) through effects on inflammation, myelination and neurodegeneration, and exogenous hormones have been explored for their therapeutic potential. However, our understanding of how sex hormones influence MS disease processes and outcomes remains incomplete. Furthermore, our current knowledge is derived primarily from studies that focus exclusively on cisgender populations with exclusion of gender-diverse people.

View Article and Find Full Text PDF

Objective: It is unknown whether delay in diagnosis affects morbidity reportedly in paraneoplastic syndromes (PNS). We aimed to explore various aspects of PNS, including prevalence, clinical characteristics, diagnostic criteria, and treatment outcomes.

Methods: We studied n-PNS diagnosis between 2016 to 2023, and included only patients with positive onconeural antibodies, who developed cancer, and exhibited a recognizable PNS phenotype.

View Article and Find Full Text PDF

HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a chronic, progressive neurological disorder and shares many radiological and clinical features with other more prevalent myelopathies. Here, we quantified spinal cord and brain volumes in adults with HAM/TSP in comparison with healthy volunteers (HVs) and individuals diagnosed with relapsing-remitting or progressive multiple sclerosis (RRMS or P-MS). Clinical disability and MRI were assessed in 24 HVs, 43 HAM/TSP subjects, and 46 MS subjects.

View Article and Find Full Text PDF

Aquaporin-4 Immunoglobulin G-seropositive Neuromyelitis Optica Spectrum Disorder MRI Characteristics: Data Analysis from the International Real-World PAMRINO Study Cohort.

Radiology

November 2024

From the Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin & Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Lindenberger Weg 80, 13125 Berlin, Germany (C.C., H.Z., A.U.B., F.P.); NeuroCure Clinical Research Ctr (C.C., H.Z., A.U.B., J.W., F.P.), Dept of Psychiatry and Neurosciences, Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany (C.C.); Medical Image Analysis Center, Basel, Switzerland (V.C.e.S., E.G., D.M.); Paulista School of Medicine, Dept of Neurology and Neurosurgery (D.B.B.), Dept of Diagnostic Imaging, Universidade Federal de São Paulo, São Paulo, Brazil (M.I.I.); Koc Univ, School of Medicine Neurology Dept and Istanbul Univ, Cerrahpasa School of Medicine, Neurology Dept, Istanbul, Turkey (A.A.); Dept of Neurology, Istanbul Univ, Cerrahpasa Faculty of Medicine, Istanbul, Turkey (U.T.); Div of Neurology, Dept of Medicine, Siriraj Hosp, Mahidol Univ, Bangkok, Thailand (S.S.); Bumrungrad International Hosp, Bangkok, Thailand (S.S.); Center for Advanced Neurologic Research, KS Hegde Medical Academy, Nitte Univ, Mangalore, India (L.P., A.D.); Dept of Neurology, Hosp de S. João, Al. Hernâni Monteiro, Porto, Portugal (M.J.S., R.F.); MS Center at Swedish Neuroscience Inst, Seattle, Wash (P.Q., C.T.); Dept of Neurology and Neuroimmunology Clinic, Rabin Medical Center, Petach Tikva, Israel (I.L.); Sackler Faculty of Medicine & Felsenstein Medical Research Center, Tel Aviv Univ, Tel Aviv, Israel (I.L., H.S.K.); Dept of Radiology, Rabin Medical Center, Beilinson Hosp, Israel, and Sackler Faculty of Medicine, Tel-Aviv Univ, Tel Aviv, Israel (V.K.); Dept of Neurology and Neuroimmunology, Rabin Medical Center, Beilinson Hosp, Israel, and Sackler Faculty of Medicine, Tel-Aviv Univ, Tel Aviv, Israel (M.A.H.); Neuro-Ophthalmology Div, Dept of Ophthalmology, Rabin Medical Center, Petah Tikva, Israel (H.S.K.); Div of Neurology, Univ of Toronto, St Michael's Hosp, Toronto, Canada (D.L.R., L.W.); Mellen Center, Cleveland Clinic, Cleveland, Ohio (D.O.), Dept of Biomedical Engineering, Cleveland Clinic, Cleveland, Ohio (K.N.); Multiple Sclerosis and Neuroimmunology Program, Univ Hosps of Cleveland, Case Western Reserve Univ School of Medicine, Cleveland, Ohio (H.A., M.O.S.); Michigan Inst for Neurologic Disorders, Farmington Hills, Mich (Y.M.D.); Inst of Clinical Neuroimmunology, LMU Hosp, Ludwig-Maximillians Universität München, Munich, Germany (J.H.); Dept of Neurology, Slagelse Hosps, Odense, Denmark (N.A.); Insts of Regional Health Research & Molecular Medicine, Univ of Southern Denmark, Odense, Denmark (N.A.); Dept of Radiology, Aleris Hosp, Copenhagen, Denmark (P.B.S.); NYU Multiple Sclerosis Comprehensive Care Center, Dept of Neurology, NYU School of Medicine, New York, NY (I.K.); Dept of Neurology, Center for Neurology and Neuropsychiatry, LVR-Klinikum, Heinrich Heine Univ Düsseldorf, Düsseldorf, Germany (M.R.); School of Medicine and Dentistry, Gold Coast Campus, Griffith Univ, Queensland, Australia (S.B., S.A.); Dept of Neurology, Gold Coast Univ Hosp, Queensland, Australia (S.A.); Dept of Pediatrics, Univ of Utah, Salt Lake City, Utah (B.M., A.M.J., M.W., S.G., L.J.C.); Dept of Medicine, Divs of Molecular Medicine & Infectious Diseases, and Ludquist Inst for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, Calif (M.R.Y.); Dept of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, Calif (M.R.Y.); Depts of Ophthalmology and Visual Sciences, Kellogg Eye Center, Univ of Michigan, Ann Arbor, Mich (T.J.S.); Div of Metabolism, Endocrine and Diabetes, Dept of Internal Medicine, Univ of Michigan Medical School, Ann Arbor, Mich (T.J.S.); Hoffmann-LaRoche, Basel, Switzerland (J.W.); Dept of Neurology, Charité-Universitätsmedizin Berlin, Germany (F.P.); Affiliated author members of the Guthy-Jackson Charitable Foundation (GJCF) International Clinical Consortium (ICC) for NMOSD are listed in Appendix S1.

Article Synopsis
  • Patients with neuromyelitis optica spectrum disorder (NMOSD) often have antibodies against aquaporin-4 (AQP4), making MRI monitoring critical for understanding the disease's progression.
  • A retrospective study involved MRI data from 525 AQP4-IgG-seropositive NMOSD patients across 11 countries, focusing on the types and locations of lesions in the central nervous system.
  • Results showed a high prevalence of hyperintense lesions in the brain and significant patterns of myelitis in the spinal cord, emphasizing the importance of MRI in tracking this condition.
View Article and Find Full Text PDF

How to avoid missing a diagnosis of neuromyelitis optica spectrum disorder.

Mult Scler

January 2025

NeuroCure Clinical Research Center, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.

Recognizing neuromyelitis optica spectrum disorder (NMOSD) and differentiating NMOSD from multiple sclerosis (MS) and other disorders can be challenging yet it is extremely important to prevent misdiagnosis, defined in this review as the incorrect diagnosis of patients who truly have NMOSD, particularly in aquaporin-4-IgG (AQP4-IgG)-seronegative cases. The heterogeneity of clinical presentations and wide range of differential diagnoses often lead to missed diagnoses of NMOSD. Misapplication of the 2015 NMOSD criteria and misinterpretation of clinical and neuroradiological findings are relevant factors associated with misdiagnosis in clinical practice.

View Article and Find Full Text PDF

Background: We assessed the effectiveness, safety and patient-reported outcomes (PROs) of dimethyl fumarate (DMF) in real-world clinical practice in patients with multiple sclerosis (PwMS) from Argentina.

Methods: We conducted a multicenter ambispective cohort study in Argentina between September 2020 and March 2023. Changes in annualized relapse rate (ARR), Expanded Disability Status Scale (EDSS) score, magnetic resonance imaging (MRI), no evidence of disease activity (NEDA), PROs (depression, anxiety, fatigue, burden of treatment and quality of life), and safety data were collected at clinical visits performed every 6 months for at least 24 months.

View Article and Find Full Text PDF

Epstein-Barr virus (EBV) is an aetiologic risk factor for the development of multiple sclerosis (MS). However, the role of EBV-infected B cells in the immunopathology of MS is not well understood. Here we characterized spontaneous lymphoblastoid cell lines (SLCLs) isolated from MS patients and healthy controls (HC) ex vivo to study EBV and host gene expression in the context of an individual's endogenous EBV.

View Article and Find Full Text PDF

In the United States, the 40 colleges of osteopathic medicine and 157 schools of allopathic medicine face challenges in recruiting candidates who are underrepresented in medicine (URiM), and gaps in racial disparity appear to be widening. In this commentary, the authors provide an analysis of the data collected from 8 years of conducting a URiM recruitment and welcoming social events. The event is sponsored by a student special interest group called Creating Osteopathic Minority Physicians Who Achieve Scholastic Success (COMPASS) at the Touro College of Osteopathic Medicine - New York (TouroCOM-NY).

View Article and Find Full Text PDF

Autistic spectrum disorders (ASD) in children are becoming increasingly common, reaching epidemic proportions. Among the various causes contributing to the development of ASD, the leading place belongs to both chromosomal pathologies and genetic syndromes and their consequence - metabolic imbalance or severe metabolic disorders. Depending on the degree of metabolic pathway damage, certain phenotypes of ASD are formed.

View Article and Find Full Text PDF

A mixture model for differentiating longitudinal courses of multiple sclerosis.

Mult Scler Relat Disord

January 2024

Neuroimmunology Clinic, Disciplina de Neurologia, Escola Paulista de Medicina - Universidade Federal de São Paulo, Sao Paulo, Brazil.

Background: Multiple sclerosis has a broad spectrum of clinical courses. Early identification of patients at greater risk of accumulating disability is essential.

Objectives: Identify groups of patients with similar presentation through a mixture model and predict their trajectories over the years.

View Article and Find Full Text PDF

Pseudocystic demyelination in multiple sclerosis.

Mult Scler

September 2023

MS & Neuroimmunology Clinic, Concord Hospital, The University of Sydney, Sydney, NSW, Australia.

View Article and Find Full Text PDF

Advancing Health Equity in Neurologic Disorders and Stroke: Stakeholder Insights Into Health Disparities, Research Gaps, and Potential Interventions.

Neurology

August 2023

From the Office of Global Health and Health Disparities (E.L.L., N.E.B., S.C., C.A.S., R.T.B.), Division of Clinical Research, Division of Extramural Research, and Neuroimmunology Clinic (J.A.A.), Division of Intramural Research, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD.

Objectives: The purpose of this study was to analyze the National Institute of Neurological Disorders and Stroke (NINDS) Request for Information (RFI) input from the public-including health care providers, researchers, patients, patient advocates, caregivers, advocacy organizations, professional societies, and private and academic stakeholders with an interest in health disparities (HDs) in neurologic disease. RFI questions were structured to solicit input on what stakeholders believe are neurologic disease HD research priorities, drivers of health inequity, and potential interventions. Furthermore, these stakeholder insights were examined within the context of contemporary scientific literature and research frameworks on health equity and health disparities.

View Article and Find Full Text PDF

Introduction: People with multiple sclerosis (pwMS) may suffer from some degree of impaired social cognition (SC), the process that integrates the mental operations underlying social interactions. SC is still not clearly characterized in the early stages of MS, and it is not defined whether SC is independent of cognitive impairment.

Methods: In this cross-sectional study, we aimed to compare SC measures in a population of early (≤5 years) relapsing-remitting MS (RRMS) with an age, sex, and education-matched control group.

View Article and Find Full Text PDF

EBNA1 Inhibitors Block Proliferation of Spontaneous Lymphoblastoid Cell Lines From Patients With Multiple Sclerosis and Healthy Controls.

Neurol Neuroimmunol Neuroinflamm

September 2023

From the Neuroimmunology Branch (M.C.G.M., A.C., R.J.H., S.J.), National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD; The Wistar Institute (S.S.S., C.S., J.F.C., R.J.P., F.L., T.E.M., P.M.L.), Philadelphia, PA; and Neuroimmunology Clinic (F.C.A., J.O.), National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD.

Background And Objectives: Epstein-Barr virus (EBV) is a ubiquitous herpesvirus that establishes lifelong latency in memory B cells and has been identified as a major risk factor of multiple sclerosis (MS). B cell depletion therapies have disease-modifying benefit in MS. However, it is unclear whether this benefit is partly attributable to the elimination of EBV B cells.

View Article and Find Full Text PDF

Olfactory function in Susac syndrome.

Clin Neurol Neurosurg

October 2023

Department of Neurology, Sourasky Tel Aviv Medical Center, Tel Aviv, Israel; Neuroimmunology Unit, Neurological Institute Aviv Medical Center, Tel Aviv, Israel.

Objectives: Susac syndrome is a rare autoimmune endotheliopathy involving the brain, retina, and inner ear. Olfactory dysfunction is a common early manifestation of several central nervous system diseases, including neurodegenerative diseases and autoimmune-mediated diseases such as Multiple Sclerosis. While the literature is abundant about the Susac syndrome classic triad of encephalopathy, branch retinal artery occlusion, and low-frequency sensorineural hearing loss, little is known about the extent of olfactory sense involvement.

View Article and Find Full Text PDF

Highly Sensitive 3-Tesla Real Inversion Recovery MRI Detects Leptomeningeal Contrast Enhancement in Chronic Active Multiple Sclerosis.

Invest Radiol

March 2024

From the Translational Neuroradiology Section, National Institute of Neurological Disorders and Stroke, National Institute of Health, Bethesda, MD, USA (S.V.O., E.S.B., M.I.G., M.A., D.S.R.); qMRI Core facility, National Institute of Neurological Disorders and Stroke, National Institute of Health, Bethesda, MD, USA (H.D., G.N.); Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA (E.S.B.); Office of Biostatistics, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA (G.N.); Department of Radiology and Radiological Sciences, Uniformed Services University of the Health Sciences, Bethesda, MD, USA (D.L.P.); Division of Neuroscience, Vita-Salute San Raffaele University and Hospital, Milan, Italy (M.A.); Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA (M.A.); Experimental Immunotherapeutics Unit, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA (I.C.M.C.); Neuroimmunology Clinic, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA (A.F.); and Viral Immunology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD20814, USA (S.J.).

Article Synopsis
  • Leptomeningeal contrast enhancement (LME) on T2-FLAIR MRI is linked to leptomeningeal inflammation in multiple sclerosis (MS), but often misses cases, with only ~25% detection in patients.
  • An optimized 3D Real-IR MRI sequence was tested on 177 scans, revealing significantly higher prevalence of LME (73%) compared to T2-FLAIR (33%) and greater sensitivity with 3.7-fold more foci detected.
  • Age was a key factor in LME status, and while LME was not linked to cortical lesions, it correlated with paramagnetic rim lesions, indicating Real-IR's potential for better identifying MS-related changes.
View Article and Find Full Text PDF

Toward a serum biomarker of disease activity in Susac syndrome.

Eur J Neurol

October 2023

Multiple Sclerosis and Neuroimmunology Clinic, Concord Repatriation General Hospital, University of Sydney, Sydney, New South Wales, Australia.

View Article and Find Full Text PDF

Intravenous immunoglobulin treatment for acute attacks in myelin oligodendrocyte glycoprotein antibody disease.

Mult Scler

August 2023

Neuroimmunology Clinic and Research Laboratory, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Article Synopsis
  • A study investigated the effectiveness of intravenous immunoglobulins (IVIGs) for treating acute myelin oligodendrocyte glycoprotein antibody disease (MOGAD) attacks.
  • The research involved analyzing data from 39 patients across seven neuroimmunology centers, focusing on patient demographics and symptoms before and after IVIG treatment.
  • Results showed significant improvements in disability and visual acuity following IVIG administration, suggesting it may be a beneficial treatment for MOGAD, although further studies are needed to confirm these findings.
View Article and Find Full Text PDF

Electrophysiological and Histological Correlations of Optic Neuritis in the Dark Agouti Rat Model of Experimental Autoimmune Encephalomyelitis.

Neuroscience

August 2023

Neuroimmunology Clinic and Research Laboratory, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Experimental autoimmune encephalomyelitis (EAE) is an animal model of Inflammatory central nervous system (CNS) disease. Dark agouti (DA) rats immunized with full-length myelin oligodendrocyte glycoprotein (MOG) typically develop a relapsing-remitting EAE form characterized by predominant demyelinating involvement of the spinal cord and optic nerve. Visually evoked potentials (VEP) are a useful objective tool to assess the optic nerve function and monitor electrophysiological changes in optic neuritis (ON).

View Article and Find Full Text PDF

Importance: Progressive multifocal leukoencephalopathy can occur in the context of systemic sarcoidosis (S-PML) in the absence of therapeutic immune suppression and can initially be mistaken for neurosarcoidosis or other complications of sarcoidosis. Earlier recognition of S-PML could lead to more effective treatment of the disease.

Objective: To describe characteristics of patients with S-PML.

View Article and Find Full Text PDF

Low mortality rate in a large cohort of myelin oligodendrocyte glycoprotein antibody disease (MOGAD).

Ann Clin Transl Neurol

April 2023

Neuroimmunology Clinic and Research Laboratory, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Article Synopsis
  • * In a large cohort of patients, none died, leading to an estimated upper limit of a 95% confidence interval showing a crude mortality rate of 2.1%.
  • * The findings suggest that MOGAD mortality is lower than in other neuroinflammatory diseases and similar to age-adjusted mortality rates in the general U.S. population, but further research is needed to confirm these results.
View Article and Find Full Text PDF

Many early-career neuroscientists with diverse identities may not have mentors who are more advanced in the neuroscience pipeline and have a congruent identity due to historic biases, laws, and policies impacting access to education. Cross-identity mentoring relationships pose challenges and power imbalances that impact the retention of diverse early career neuroscientists, but also hold the potential for a mutually enriching and collaborative relationship that fosters the mentee's success. Additionally, the barriers faced by diverse mentees and their mentorship needs may evolve with career progression and require developmental considerations.

View Article and Find Full Text PDF